



Published in final edited form as:

Lancet Infect Dis. 2020 May ; 20(5): 538–539. doi:10.1016/S1473-3099(20)30279-6.

M1_{UK} lineage in invasive group A streptococcus isolates from the USA

Yuan Li, Srinivas Acharya Nanduri, Chris A Van Beneden, Bernard W Beall

Respiratory Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA

Nicola N Lynskey and colleagues¹ reported that a hypervirulent clone of *emm1* group A streptococcus (M1_{UK}), characterised by increased streptococcal pyrogenic exotoxin A (SpeA) production, has rapidly emerged in the UK since 2014. Large-scale genomic examinations of this M1_{UK} clade indicated a single lineage in the global group A streptococcus genomic databases, with only one isolate identified in the USA in 2015.^{1,2} We investigated whether the M1_{UK} lineage has expanded in the USA since 2015 using data from the Active Bacterial Core surveillance (ABCs) system of the US Centers for Disease Control and Prevention.

From 2015 to 2018, 7366 cases of invasive group A streptococcus infection were identified by the ABCs system, and 6335 (86.0%) isolates were characterised by whole-genome sequencing.³ Among the characterised isolates, 1052 (16.6%) were *emm1*. Mapping the sequencing reads against the M1 reference genome MGAS5005⁴ identified ten isolates carrying all 27 single-nucleotide polymorphisms (SNPs) unique to the M1_{UK} lineage and one isolate carrying 26 of these SNPs. The 11 isolates (M1_{UK_USA}) clustered together with M1_{UK} isolates randomly selected with R software (version 3.4.3) from a previous molecular mapping study¹ (figure), and their distances to the most recent common ancestor ranged from six to 23 SNPs. Analysis of phylogeny temporal structure suggested the ancestor had originated around June, 2012. Three M1_{UK_USA} isolates from New York state in 2016 differed from each other by a maximum of three SNPs, consistent with close transmission links within a disease cluster.

Between 2015 and 2018, the numbers of M1_{UK_USA} group A streptococcus isolates (and proportions of total *emm1*) identified each year were one of 308 (0.3%), seven of 254 (2.8%), none of 312 (0%), and three of 178 (1.7%), respectively. We found no evidence of M1_{UK_USA} lineage expansion in the ABCs system (Cochran-Armitage test, $p=0.36$). The 11 M1_{UK_USA} group A streptococcus isolates were observed in six different states, and in each state the lineage was seen only in a single year (figure). Syndromes caused by the M1_{UK_USA} lineage in patients were cellulitis (four patients), pneumonia (three patients), primary bacteraemia (one patient), necrotising fasciitis (one patient), streptococcal toxic shock syndrome (one patient), septic shock (one patient), septic arthritis (one

yqh8@cdc.gov .

We declare no competing interests. The findings and conclusions of this Correspondence are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.

patient), empyema (one patient), and abscesses (one patient). Three (27·3%) of the 11 patients infected by the M1_{UK_USA} lineage died (one with primary bacteraemia, one with streptococcal toxic shock syndrome, and one with septic shock), two of whom were within the New York cluster. This case fatality ratio was higher than that observed among patients infected by non-M1_{UK_USA} *emm1* group A streptococcus (160 [15·4%] of 1041), but the difference was not significant (Fisher's exact test, $p=0\cdot39$).

In summary, the M1_{UK} lineage was seen in diverse geographic regions, formed a local disease cluster, and caused severe infection syndromes in the USA from 2015 to 2018. Although this clone did not expand substantially according to data in the ABCs system, continued genomic surveillance is needed to monitor the effects of this and other emerging virulent strains.

References

1. Lynskey NN, Jauneikaite E, Li HK, et al. Emergence of dominant toxigenic M1T1 *Streptococcus pyogenes* clone during increased scarlet fever activity in England: a population-based molecular epidemiological study. *Lancet Infect Dis* 2019; 19: 1209–18. [PubMed: 31519541]
2. Demczuk W, Martin I, Domingo FR, MacDonald D, Mulvey MR. Identification of *Streptococcus pyogenes* M1_{UK} clone in Canada. *Lancet Infect Dis* 2019; 19: 1284–85.
3. Chochua S, Metcalf BJ, Li Z, et al. Population and whole genome sequence based characterization of invasive group A streptococci recovered in the United States during 2015. *mBio* 2017; 8: e01422–17. [PubMed: 28928212]
4. Sumby P, Porcella SF, Madrigal AG, et al. Evolutionary origin and emergence of a highly successful clone of serotype M1 group a *Streptococcus* involved multiple horizontal gene transfer events. *J Infect Dis* 2005; 192: 771–82. [PubMed: 16088826]




Figure: Phylogenetic relationship of the UK and USA isolates belonging to the M1_{UK} lineage

A maximum likelihood phylogenetic tree was constructed from core SNPs (excluding those potentially acquired by horizontal gene transfer) of *emm1* group A streptococcus isolates, including the 11 M1_{UK_USA} isolates, six M1_{inter_USA} isolates identified in our whole-genome sequencing analysis (M1_{inter} isolates have been reported previously;¹ M1_{inter_USA} isolates contained eight to 13 of the 27 lineage-defining SNPs of M1_{UK}), and 29 randomly selected M1_{global_USA} isolates (held in the Active Bacterial Core surveillance system) from the USA, as well as four randomly selected M1_{UK} isolates, three randomly selected M1_{inter} isolates, and three randomly selected M1_{global} isolates from the UK.¹ Shading highlights the M1_{UK} lineage. The scale bar represents the expected nucleotide substitutions per site. The inset shows the genetic relatedness of the 11 M1_{UK_USA} isolates. Branch length is dictated by SNP difference. SNP=single-nucleotide polymorphism. *Fatal cases.